Supported by five independent studies8,12–15,17, the TP53 noncoding variant (rs78378222[C]) increases glioma risk more significantly than for other tumors with an odds ratio (OR) ranging from 2.35 to 3.74 (Supplementary Table 1). This evidence concerns the gene TP53 and central nervous system cancer.